Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024. The company, incorporated in British Columbia and operating under the industrial classification code number 2834, aims to commence the proposed sale of securities to the public as soon as practicable after the effective date of the registration statement. Clearmind Medicine, trading under the symbol 'CMND' on the Nasdaq Capital Market, has outlined a preliminary prospectus dated February 7, 2024, for the resale of up to 1,500,000 common shares. These shares are related to warrants originally issued in a private placement on January 16, 2024. The selling shareholders, identified in the prospectus, will not provide any proceeds from...Show More

Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024. The company, incorporated in British Columbia and operating under the industrial classification code number 2834, aims to commence the proposed sale of securities to the public as soon as practicable after the effective date of the registration statement. Clearmind Medicine, trading under the symbol 'CMND' on the Nasdaq Capital Market, has outlined a preliminary prospectus dated February 7, 2024, for the resale of up to 1,500,000 common shares. These shares are related to warrants originally issued in a private placement on January 16, 2024. The selling shareholders, identified in the prospectus, will not provide any proceeds from the sale to Clearmind Medicine. However, the company may receive proceeds from the exercise of warrants if not done on a cashless basis. The common shares are currently traded on the Nasdaq, the Canadian Securities Exchange (CSE), and the Frankfurt Stock Exchange (FSE), with the last reported sale prices on February 6, 2024, being $1.56, CAD$2.10, and EUR 1.58 per share, respectively. Clearmind Medicine identifies as an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.